Abstract
INTRODUCTION
Specific features of subjective cognitive decline (SCD-plus) have been proposed to indicate an increased risk of preclinical Alzheimer’s disease (AD). However, few studies have examined how these features relate to AD biomarkers in cognitively unimpaired (CU) older adults.
METHODS
Meta-analyses were performed using cross-sectional data from nine cohorts (n = 7219, mean age (SD): 71.17 (5.9), 56.5% female) to determine associations of SCD-plus features with positron emission tomography (PET)– or cerebrospinal fluid (CSF)–derived amyloid beta (Aβ) and tau biomarkers.
RESULTS
Participants with preclinical AD (community-based only) were more likely to fulfill SCD-plus features. The presence of self-reported memory decline, associated concern/worry, and a higher number of fulfilled features were all associated with high Aβ levels. Only the latter was associated with abnormal tau.
DISCUSSION
Simultaneous endorsement of multiple SCD-plus features is a robust indicator of abnormal AD biomarkers in CU older adults, whereas isolated SCD features seem only sensitive to elevated Aβ, supporting their value as early behavioral markers of preclinical AD.
Highlights
About two-tenths of our sample had abnormal amyloid beta (Aβ) levels with evidence of subjective cognitive decline (SCD).
Preclinical AD subsamples (community-based) had a higher percentage of participants meeting SCD-plus features. Self-reported memory decline and concern/worry were the sole features associated with high Aβ, but not tau, burden.
A higher number of fulfilled SCD-plus features are linked to high Aβ and tau burden.
Use of multiple SCD-plus features may help identify early stages of biological AD.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Elizabeth Kuhn,
Hannah M. Klinger,
Rebecca E. Amariglio,
Michael Wagner,
Frank Jessen,
Emrah Düzel,
Michael T. Heneka,
Gael Chételat,
Dorene M. Rentz,
Reisa A. Sperling,
Jarith L. Ebenau,
Elke Butterbrod,
Wiesje M. Van Der Flier,
Sietske A. M. Sikkes,
Charlotte E. Teunnissen,
Argonde C. Van Harten,
Elsmarieke M. Van De Giessen,
Lorena Rami,
Adria Tort,
Gonzalo Sánchez Benavides,
Katherine A. Gifford,
Carol Van Hulle,
Rachel F. Buckley,
Alzheimer’s Disease Neuroimaging Initiative,
Australian Imaging Biomarkers and Lifestyle flagship study of ageing, A4 Study Team,
DELCODE Study,
Harvard Aging Brain Study,
Frederic Brosseron,
Katharina Buerger,
Christoph Laske,
Robert Perneczky,
Oliver Peters,
Joseph Priller,
Alfredo Ramirez,
Anja Schneider,
Annika Spottke,
Stefan Teipel,
Jens Wiltfang | February 22, 2025